Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Al-Ola A AbdallahDaisy AlapatVarinder KaurShebli AtrashPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Our single institution experience shows that ASCT is feasible for cardiac amyloidosis and/or cardiac LCDD. However, careful selection of proper patients and diligent supportive care are vital to decreasing transplant-related mortality.
Keyphrases
- left ventricular
- stem cells
- end stage renal disease
- healthcare
- newly diagnosed
- chronic kidney disease
- palliative care
- bone marrow
- heart failure
- peritoneal dialysis
- multiple myeloma
- cardiovascular disease
- cell therapy
- quality improvement
- metabolic syndrome
- coronary artery disease
- insulin resistance
- mesenchymal stem cells
- platelet rich plasma
- health insurance